Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04521114 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT04521114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2020
Completion date
December 29, 2021
Enrollment
87 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)